Innate Pharma SA
NASDAQ:IPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
NASDAQ:IPHA
|
FR |
|
B
|
Bravura Solutions Ltd
F:BRA
|
AU |
|
Made Tech Group PLC
F:5UH
|
UK |
|
Kofola CeskoSlovensko as
F:48K
|
CZ |
|
A
|
AT & S Austria Technologie & Systemtechnik AG
XMUN:AUS
|
AT |
|
British Land Company PLC
F:BLDA
|
UK |
|
Alphawave IP Group PLC
F:7GL
|
UK |
|
Trend Micro Inc
F:TMI
|
JP |
|
S
|
Sahakol Equipment PCL
SET:SQ
|
TH |
|
Xtract One Technologies Inc.
OTC:XTRAF
|
CA |
|
AT & S Austria Technologie & Systemtechnik AG
F:AUS
|
AT |
Wall St Price Targets
IPHA Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPHA is 6.06 USD with a low forecast of 5.05 USD and a high forecast of 7.23 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPHA's stock price target?
Price Target
6.06
USD
According to Wall Street analysts, the average 1-year price target for IPHA is 6.06 USD with a low forecast of 5.05 USD and a high forecast of 7.23 USD.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
174%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 3 years is 174%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
